A Phase 1 interventional study of YK012 in Primary Membranous Nephropathy, sponsored by Excyte Biopharma Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Excyte Biopharma Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
This study's planned enrollment of 66 is above the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Browse Glomerulonephritis, Membranous studies →Excyte Biopharma Ltd is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with primary membranous nephropathy will receive ascending doses of YK012 infusion to evaluate the safety and tolerability of YK012, and to determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)
Drug: YK012
Participants will receive 2 different doses of YK012 infusion to evaluate the safety and tolerability of YK012 in participants with primary membranous nephropathy and to establish the Recommended Phase II Dose (RP2D).
Drug: YK012
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Ia: Dose-Limiting Toxicity (DLT)
Time frame: up to 28 days after the first dose
Adverse Event (AE)
Time frame: From the first induction to the end of the trial at 53 weeks
Severe Adverse Event
Time frame: From the first induction to the end of the trial at 53 weeks
Area under the concentration-time curve (AUC0-t)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Area under the concentration-time curve from time 0 to ∞ (AUC0-∞)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Maximum plasma concentration (Cmax)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Time to reach maximum concentration (Tmax)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Half-life (t1/2)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Apparent clearance (CL)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
apparent volume of distribution (Vd)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Minimum plasma concentration (Cmin)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Time to onset and duration of peripheral blood B-cell and B-cell subset depletion
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Changes in peripheral blood Natural Killer (NK) cells
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Changes in peripheral blood T cells and T cell subsets (CD4+ T cells, CD8+ T cells)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
The profile of cytokine changes
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Positive rates of blood anti-drug antibody (ADA) and neutralizing antibody (Nab)
Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks
Changes from baseline in 24-hour urine protein during the trial period
Time frame: From screening to the end of the trial at 53 or 77 weeks
Changes from baseline in estimated glomerular filtration rate (eGFR) during the trial period
Time frame: From screening to the end of the trial at 53 or 77 weeks
Changes from baseline in anti-phospholipase A2 receptor (PLA2R) antibody titer during the trial period
Time frame: From screening to the end of the trial at 53 or 77 weeks
Proportion of participants achieving overall renal remission (ORR)
Time frame: From screening to the end of the trial at 53 or 77 weeks
Proportion of participants achieving Complete Response (CR) and Partial Response (PR)
Time frame: From screening to the end of the trial at 53 or 77 weeks
Proportion of participants achieving immunological remission
Time frame: From screening to the end of the trial at 53 or 77 weeks
Time to achieve CR
Time frame: From screening to the end of the trial at 53 or 77 weeks
Time to achieve ORR
Time frame: From screening to the end of the trial at 53 or 77 weeks
Duration of CR
Time frame: From screening to the end of the trial at 53 or 77 weeks
Duration of ORR
Time frame: From screening to the end of the trial at 53 or 77 weeks
Proportion of participants with treatment failure
Time frame: From screening to the end of the trial at 53 or 77 weeks
Proportion of participants who relapsed
Time frame: From screening to the end of the trial at 53 or 77 weeks
No study locations are listed for this record.
Start is estimated for Sep 2027; primary completion for Oct 2028, 13 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Oct 2026 → Sep 2027, primary completion Nov 2027 → Oct 2028 and completion Feb 2028 → Jan 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: YK012
Glomerulonephritis, Membranous →
Excyte Biopharma Ltd